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1. Introduction 
Genomic DNA is the decisive blueprint of our heredity and 
carries an immense corpus of information
1
. Collection and 
recovery of the information pertaining to the lineage commitment 
of the cell is controlled by the transcriptional machinery
2
. 
Misregulation of transcription is associated with at least 50% of 
tumors
3
. Therefore, the development of artificial transcriptional 
activators that can restore and regulate the expression of 
perturbed genes is undergoing vigorous study owing to their 
versatile medicinal applications
4–6
. Factors that can modulate the 
nucleobases of DNA will also have a significant impact on the 
cell fate. Consequently, naturally occurring DNA-binding 
proteins have been investigated for their medicinal applications
7
. 
Programmable natural transcriptional activators, such as designer 
polydactyl zinc fingers, homing endonucleases, and transcription 




   Ever since the elucidation of the genetic code, it has been clear 
that genome information alone is insufficient to control gene 
expression, because humans and Drosophila have almost the 
same numbers of gene families
11
. In nature, gene expression is 
precisely regulated at the epigenetic level, and this predominantly 
involves the modification of histone proteins, which are 
suggested to have a code of their own, the histone code
12
. 
However, none of the known transcriptional activators can be 
developed as a genetic switch because they lack the consideration 
of the most critical epigenetic constraints
13
. 
The artificial transcriptional activation of pluripotency in 
somatic cells to generate induced pluripotent stem cells (iPSCs) 
has brought us a step closer to customized patient-specific cell 
therapies
14–16
. However, although promising, iPSC techniques 
have several shortcomings, such as the potential of retroviruses to 
cause tumors in tissues derived from host iPSCs, the low 
efficiency of induction, the limited duration of the 
reprogramming process, and the need for drug-resistance-based 
selection
17
. Despite recent promising breakthroughs, the clinical 
translation of iPSCs is still hindered by various phenomena, 
including the retention of epigenetic memory
18,19
. Epigenetic 
modifiers, including DNA methyltransferase (DNMT) inhibitors 
and/or histone deacetylase (HDAC) inhibitors, have been shown 
to enhance reprogramming efficiency
20–22
. However, the 
aforementioned chromatin modifiers lack selectivity, and because 
chromatin modification can induce heritable cell states, their 
precise application is essential for the safe clinical use of iPSCs. 
Recently, we have developed artificial transcriptional 
activators that include sequence-specific hairpin pyrrole–
imidazole (PI) polyamides conjugated with chromatin-modifying 
suberoylanilide hydroxamic acid (SAHA)
23
. Unlike other 
programmable DNA binding molecules, PI polyamide–SAHA 
conjugates are also epigenetically active
24
. Mouse embryonic 
fibroblast (MEF) cells were treated individually with a total of 16 
PI polyamide–SAHA conjugates, and the effects of the 
conjugates on the expression of iPSC factors were screened. Our 
results indicated that PI polyamide–SAHA conjugate 1 (Fig. 1) 
increased the expression of Oct-3/4 and Nanog by about three-
fold. About 1.5–2-fold increase were also observed in the 
expression of Sox2, Klf4, and c-Myc
24
. In this paper, the design 
and synthesis of derivatives of the successful PI polyamide–
SAHA conjugate 1 are reported, together with their effects on the 
expression patterns of five iPSC factors. Our results indicate that 
these programmable small DNA-binding molecules, which 
induce the epigenetic activation of specific gene(s), can be 
developed to induce the specific expression of core pluripotency 




ARTICLE  INFO ABSTRACT  
Article history: 
 
Epigenetic modifications that govern the gene expression are often overlooked with the design of 
artificial genetic switches. N-Methylpyrrole-N-methylimidazole (PI) hairpin polyamides are 
programmable small DNA binding molecules that have been studied in the context of gene regulation. 
Recently, we synthesized a library of compounds by conjugating PI polyamides with SAHA, a 
chromatin-modifier. Among these novel compounds, PI polyamide–SAHA conjugate 1 was shown to 
epigenetically activate pluripotency genes in mouse embryonic fibroblats. Here, we report the 
synthesis of the derivatives of conjugate 1 and demonstrate that these epigenetically active molecules 











Figure 1. Chemical structures of SAHA and the synthetic PI polyamide–
SAHA conjugate 1-6. 
 
2. Synthesis of derivatives of PI polyamide–SAHA conjugate 1 
 In this study, we designed five derivatives of PI polyamide–
SAHA conjugate 1 to target a specific six-base-pair sequence 
according to the binding rule for PI polyamides (Fig. 1). We 
chose to substitute five SAHA moieties at the N-tail with a 
double -alanine linker and one SAHA moiety at the C-tail with 
an N1-(3-aminopropyl)-N1-methylpropane-1,3-diamine linker in 
the hairpin PI polyamides. To investigate the effects of 
hybridization on the PI polyamide conjugates, all the PI 
polyamides were designed with different linker distances 
between the PI polyamides and SAHA.  
 
Four PI polyamide–SAHA conjugates (2, 3, 4, and 5) were 
synthesized by Fmoc solid-phase synthesis using an oxime resin 
and subsequent 3-(dimethylamino)-1-propylamine treatment, 
followed by aminolysis under a 50% (v/v) NH2OH aqueous 
solution. SAHA conjugate 6 was also synthesized by Fmoc solid-
phase synthesis using an oxime resin. After N1-(3-aminopropyl)-
N1-methylpropane-1,3-diamine treatment, the C-terminal PI 
polyamide was coupled with (8-methoxy-8-
oxooctanamido)benzoic acid to produce 6 by aminolysis. Purity 
and characterization of  compounds were done as 
mentioned before24. PI polyamide with non-functional 
SAHA moeity (PIP) is used as the control. 
 
After HPLC purification, each PI polyamide–SAHA 
conjugate was confirmed by ESI–TOF–MS, and stored before the 
analysis of its biological activity. The cytotoxicity of conjugates 
1–6 was assayed as described previously
24
, and the cells were 
almost fully viable at the working concentration of the conjugates 
(100 nM) (Fig. 2). The in vitro HDAC inhibitory activity of these 
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Figure 2. Cytotoxicity assay of PI polyamide SAHA conjugate 1-6. Cell 
viability of MEF was measured after 24 h treatment of the above effectors 
with various concentrations of 0 μM, 0.01 μM, 0.1 μM, 1 μM and 10 μM 
indicated by bars in green, gray, yellow, red and blue, respectively. Each bar 
represents mean ± SD from 12 wells.  
3. Evaluation of the PI polyamide–SAHA conjugates 
3.1. Effect of PI polyamide–SAHA conjugates on Oct-3/4 
     Six PI polyamide–SAHA conjugates (1–6) were screened for 
their effects on the expression of factors responsible for the 
induction of iPSCs. Each PI polyamide–SAHA conjugate was 
adjusted to a final concentration of 100 nM in 0.1% DMSO and 
applied individually to MEF cells at 37 °C for 24 h, followed by 
RNA isolation and cDNA synthesis, as described in the 
experimental section. After normalization to house keeping genes, 
the relative expression level of each gene was analyzed, taking 
the gene expression in the DMSO-treated cells as 100%. 
Although the expression of Oct-3/4 was increased in MEF cells 
treated with all the PI polyamide–SAHA conjugates, differential 
effects on the expression of this gene were observed. A marked 
increase in the endogenous expression of Oct-3/4 was observed 
when the PI polyamide was attached to SAHA by a linker of two 
or more -alanines, and the maximum increase of about 4.5-fold 
was observed with a three--alanine linker (Fig. 3, bar 3). 
However, when the number of -alanines in the linker was 
increased to four, an increase of about 3.6-fold in the expression 
of Oct-3/4 was observed, whereas the standard PI polyamide–
SAHA conjugate 1 showed an increase of only about 3.1-fold 
(Fig. 3, bars 1 and 4, respectively). Interestingly, both the variants 
of the PI polyamide in the C-terminal region with one additional 
-alanine linker (5) and the variant attached to SAHA instead of 
to the N-terminal region (6) increased Oct-3/4 gene expression by 
only about two-fold (Fig. 3, bars 5 and 6, respectively). It is 
important to note here that the PIP and SAHA alone had almost 
no effect (Fig. 3, bars PIP and SAHA, respectively). Because 
SAHA conjugate 2 induced an increase of only about two-fold, 
conjugate 3 linked to SAHA by three -alanines was considered 




Figure 3. Distinctively programmed SAHA conjugates differentially 
upregulate the expression of Oct-3/4. qRT–PCR analysis of the expression 
levels of Oct-3/4 after treatment with 100 nM of the effectors for 24 h. Light 
gray bars represent the controls used: 0.1% DMSO, PI polyamide conjugates 
without SAHA, and SAHA alone. Dark gray bars represent the expression 
profiles of the endogenous genes induced with PI polyamide-SAHA 
conjugates 1–6. Each bar represents the mean ± SD of a 24-well plate. 
 
3.2. Effects of PI polyamide SAHA conjugates on Nanog and 
Sox2 
Together with Oct-3/4, pluripotency is co-regulated through the 
activation of Sox2 and Nanog, which are involved in the core 
transcriptional network
25
. Therefore, the effects of conjugates 1–6 
on the endogenous expression of both Nanog and Sox2 were 
studied, as mentioned above. Conjugate 1 was previously shown 
to increase Nanog expression by about 2.5-fold, and the 
expression profiles of Nanog in cells treated with conjugate 1 
derivatives were similar to those of Oct-3/4, where maximum 
induction was observed with PI polyamide–SAHA conjugate 3 
(Fig. 4, light gray bar 3). The other variants showed only a 
relative moderate increase of about two-fold in the expression of 
Nanog (Fig. 4, light gray bars 1, 2, 4, 5, and 6). Consistent with 
the previous results, the control samples containing only SAHA 
or the PIP had no effect on Nanog expression (Fig. 4, light gray 
bars DMSO, PIP, and SAHA). 
Although conjugate 1 and its derivatives also markedly 
increased Sox2 expression compared with that in the control 
samples, there were few or no differences in the effects of the 
derivatives on the Sox2 expression profile, including the 
derivative with the three--alanine linker (Fig. 4, dark gray bars). 
Thus, the expression of Nanog and Sox2 was upregulated by PI 


















Figure 4. Effects of PI polyamide-SAHA conjugates on the endogenous 
expression of Nanog and Sox2. qRT–PCR analysis was performed to 
determine the expression profiles of Nanog (light gray bar) and Sox2 (dark 
gray bar) after treatment with SAHA conjugates 1–6 or the controls (DMSO, 
SAHA only, and PI polyamide conjugates only), as described in the text. Each 
bar represents the mean ± SD of a 24-well plate. 
3.3. Effect of PI polyamide SAHA conjugates on Klf4 and c-
Myc 
A precise balance of Klf4 and c-Myc transcriptional network 
and core pluripotency genes is essential for the successful 
reprogramming of the somatic genome
26
. Conjugate 1 showed 
little or no effect on the expression of either Klf4 or c-Myc
24
. 
Interestingly, the derivatives of conjugate 1 showed different 
induction patterns from those observed for Oct-3/4, Sox2, and 
Nanog. Variations in the -alanine linker did not cause any 
significant differences in the expression profile of Klf4. 
Surprisingly, a maximum induction of about 2.2-fold in the 
expression profile of Klf4 was observed with the PI polyamide–
SAHA conjugate with SAHA attached in the C-terminal region 
(6) (Fig. 5, light gray bar 6). A similar induction pattern, with an 
increase in the expression of Klf4 of about 1.5- to 1.8-fold, was 
observed with the other variant PI polyamide conjugates. Another 
C-terminal variant with a -alanine linker (5) showed relatively 
lower induction of Klf4 (Fig. 5, light gray bar 5). However, the 
difference in activity is not remarkable to derive conclusion about 
the actual mechanism of action of these compounds 
The PI polyamide attached to SAHA by one -alanine (2) had 
almost no effect on c-Myc expression (Fig. 5, dark gray bar 2), 
whereas a slight increase of about 1.5-fold in its expression 
profile was observed with the other derivatives (Fig. 5, dark gray 
bars). A maximum increase of about 1.8-fold was induced by the 
C-terminal variant with a -alanine linker, but this increase did 
not differ significantly from those induced by the other variants. 
Nevertheless, this increase was considerable compared with the 





Figure 5. Effects of PI polyamide-SAHA conjugates on the expression of 
Klf4 and c-Myc. qRT-PCR analysis was performed with SAHA conjugates 1–
6 and controls (DMSO, SAHA only, and PI polyamide only), as described in 
the text, to obtain the expression profile of Klf4 (light gray bar) and c-Myc 
(dark gray bar). Each bar represents the mean ± SD of a 24-well plate. 
4. Discussion 
The directed chemical reprogramming of the somatic genome 
to generate iPSCs offers “paradigm-shifting opportunities”, 
including personalized renewable sources of cells for practical 
cell therapies, regenerative medicine, disease modeling, and 
prognostic toxicology applications. Therefore, transcriptional 
activators that can force the endogenous expression of the genes 
associated with pluripotency have received immense attention. 
Recently, small molecules that can replace reprogramming 
factors have been vigorously studied 
27, 28
. A recent report on the 
generation of iPSCs with a single gene, Oct-4, and small 
molecules suggests that generation of iPSCs with only small 
molecules is near the horizon
29
. Chromatin modifiers have 
already had a significant impact in improving reprogramming 
efficiency. Valproic acid and sodium butyrate notably increased 
either the three-factor reprogramming efficiency in both mouse 
and human cells or the two-factor reprogramming efficiency in 
human fibroblasts. Interestingly, SAHA, a potent HDAC 
inhibitor with a broad spectrum of epigenetic activities, displayed 
relatively mild effects
21,22
. However, at least a single transcription 
factor, Oct-3/4, is still required, and together with Nanog, it plays 
an integral role in establishing and maintaining pluripotency. 
Considering the progress in iPSC technology thus far, the precise 
activation of the core pluripotency genes should be a viable way 




In this context, the use of small selective DNA-binding 
molecules that can induce the expression of core pluripotency 
genes could be a reasonable strategy to overcome the rate-
limiting step of somatic cell reprogramming. We have shown that 
a new type of PI polyamide conjugated to the HDAC inhibitor 
SAHA can selectively acetylate the promoter region of the p16 
tumor suppressor gene in HeLa cells
23
. Because histone 














chosen as the candidate genes for screening studies of the new 
sequence-specific PI polyamide-SAHA conjugates (A–P). 
Unprecedentedly, we identified certain conjugates that could 
significantly upregulate the endogenous expression of iPSC 
factors in a differential manner
24
. Among them, PI polyamide-
SAHA conjugate 1, previously designated E, notably induced the 
expression of the core pluripotency genes Oct-3/4 and Nanog. A 
chromatin immunoprecipitation analysis (ChIP) of the Oct-3/4 
promoter region clearly suggested that conjugate 1 induced the 
enrichment of activation markers (H4Kac, H3K9ac, H3K14ac, 
and H3K4me3) and moderately reduced the expression of 
markers of repression (H3K9me3 and H3K27me3), whereas the 
control SAHA conjugate, SAHA, and DMSO had no such 
effect
24
. The sequence specificity of conjugate 1 was further 
confirmed with a ChIP analysis of the Nanog region, which 
clearly indicated that this transcriptional activation occurs only in 
the promoter and transcribed region of the gene. 
Unlike other small molecules that have been used in the 
generation of iPSCs, PI polyamide–SAHA conjugates are 
programmable because of the presence of tunable sites, which 
facilitate the covalent attachment of functional molecules
31,32
. In 
this study, we chose conjugate 1 and synthesized a series of 
derivatives that included modifications to the number of -
alanine molecules in the linker used to conjugate the PI 
polyamide with SAHA (conjugates 1–4) and variants in the C-
terminal region (conjugates 5 and 6). Three--alanine linker 
caused maximum expression of Oct-3/4 (Fig. 3, bars 1–4). While 
similar patterns were also observed for Nanog and Sox2, the 
differences between these two genes in the degree of induction 
were not striking (Fig. 4, bars 1–4), which suggests that Oct-3/4 
is the direct target of conjugate 1. In contrast, C-terminal variants 
showed relatively lower induction values (Figs. 3 and 4, bars 5 
and 6). Interestingly, a reversal in the pattern of induction was 
observed for Klf4, and the C-terminal variant conjugate 6 
produced relatively better induction than that with the various -
alanine variants (Fig. 5). Although it is known that Klf4 and c-
Myc act in a different pathway from the core pluripotency gene 
network
26
, the induction values alone is insufficient to suggest a 
different operating mechanism. Also, the actual binding site of 
our PI polyamide-SAHA conjugate is yet to be clarified. 
Nevertheless, the induction ability of our PI polyamide-SAHA 
conjugates in just 24 h could be employed to overcome the 
limitation of duration in reprogramming process.  
 
5. Conclusion 
Our results clearly suggest that a PI polyamide linked to 
SAHA by three -alanine groups increases the expression of Oct-
3/4 and Nanog. Because only PI polyamide–SAHA conjugate 1 
and not the other PI polyamide–SAHA conjugates increased the 
expression of Oct-3/4 and Nanog, sequence specificity is inferred 
to be the mechanism underlying this upregulation. Differential 
patterns of induction were also clearly observed with PI 
polyamide–SAHA conjugates 2–6, which suggests that a second 
generation of PI polyamide–SAHA conjugate 1 derivatives could 
be generated to enhance the reprogramming efficiency of somatic 
cells to iPSCs. Programmable DNA-binding molecules have been 
explored as possible candidates for artificial genetic switches. 
However, their low efficiency, attributable to their lack of 
specificity and an affinity for methylated DNA sequences, has 
been a major concern
13
. Using a predictive genomewide binding 
study across the entire sequence space and different classes of 
proteins and engineered DNA-binding molecules, Carlson et al. 
showed that the specificities of PI polyamides surpass those of 
natural DNA-binding proteins
33
. We have also demonstrated that 
PI polyamides have about a three-fold higher binding affinity for 
methylated CpG islands. Our recent report on the epigenetic 
activation of pluripotency genes by our library of designed 
SAHA conjugates and the scope of improvements shown in this 
study further substantiate the hypothesis that PI polyamide–
SAHA conjugates can be programmed for development as 
artificial genetic “ON” switches. 
6. Experiments 
6.1. General 
Reagents and solvents were purchased from standard suppliers 
and used without further purification. 
1
H-NMR spectra were 
recorded with JEOL JNM ECA-600 spectrometer operating at 
600 MHz for 
1
H NMR and tetramethylsilane was used as an 
internal standard. Proton NMR spectra were recorded in parts per 
million (ppm) downfield relative to tetramethylsilane. The 
following abbreviations apply to spin multiplicity: s (singlet), d 
(doublet), t (triplet), m (multiplet), br (broaded). High-
performance liquid chromatography (HPLC) purification was 
performed with a JASCO CCPS HPLC pump, a JASCO UV8020 
HPLC UV/VIS detector and a Chemcobond 5-ODS-H reversed 
phase column (10 x150 mm) in 0.1% TFA in water with CH3CN 
as eluent at a flow rate of 3.0 mL/min, and a linear gradient 
elution of 40–60% CH3CN over 40 min with detection at 254 nm. 
Electrospray ionization time-of-flight mass spectrometry (ESI-
TOF-MS) were produced on a BioTOF II (Bruker Daltonics) 
mass spectrometry using a positive ionization mode. All DNA 
fragments, 5’-labeled primers and cold primers were purchased 
from Sigma–Aldrich. Thermo sequence core sequencing kit was 
purchased from GE Healthcare. Polymerase chain reaction (PCR) 
was performed on an iCyclear (BIO-RAD). Machine-assisted PI 
polyamide syntheses were performed on a peptide synthesizer, 
PSSM-8 (SHIMADZU) in a stepwise reaction by Fmoc solid 
phase protocol. 
6.2. Synthesis of PI polyamide SAHA conjugates 
All machine-assisted polyamide syntheses were performed on a 
PSSM-8 peptide synthesizer (Shimadzu, Kyoto) with a computer-
assisted operation system at 40 mg of oxime resin (0.5 mmol/g, 




After the conversion to SAHA conjugates, HPLC purification 
(0.1%TFA-CH3CN 40-60% linear gradient, 0-40 min, 254 nm) 
was used to obtain the desired 1-6. 
124; ESI-TOF-MS(positive) m/z calcd for C77H96N24O15
2+［M＋
2H］2+ 799.36; found 799.16.  
2; ESI-TOF-MS(positive) m/z calcd for C74H91N23O14
2+［M＋
2H］2+ 763.86; found 763.60.  
3; 
1
H NMR (600 MHz, [D6]DMSO): = 10.33 (s, 1H), 10.28 (s, 
1H), 10.07 (s, 1H), 10.00 (s, 1H), 9.94 (s, 1H), 9.93 (s, 1H), 9.90 
(s, 2H), 9.89 (s, 1H), 9.84 (s, 1H), 9.23 (brs, 1H), 8.36 (brt, 1H), 
8.15 (brt, 1H), 8.05 (brt, 1H), 7.99 (brt, 1H), 7.92 (brt, 1H), 7.76 
(d, J =8.9Hz, 2H), 7.63 (d, J =8.9Hz, 2H), 7.39 (s, 1H), 7.27 (s, 
1H), 7.22 (s, 2H), 7.17 (s, 3H), 7.15 (s, 1H), 7.09 (s, 1H), 7.07 (s, 
2H), 7.00 (s, 1H), 6.95 (s, 1H), 6.91 (s, 1H), 6.88 (s, 1H), 3.95 (s, 
3H), 3.86 (s, 3H), 3.85 (s, 6H), 3.84 (s, 3H), 3.83 (s, 3H), 3.81 (s, 
3H), 3.80 (s, 3H), 3.22-3.31 (m, 12H), 3.06 (m, 4H), 2.81 (s, 3H), 
2.79 (s, 3H), 2.27-2.33 (m, 6H), 2.22 (t, J =7.6Hz, 2H), 1.93 (t, J 
=7.6Hz, 2H), 1.84 (m, 2H), 1.79 (m, 2H), 1.56 (m, 2H), 1.48 (m, 
2H), 1.26 (m, 2H); ESI-TOF-MS(positive) m/z calcd for 
C80H101N25O16
2+［M＋2H］2+ 834.91; found 834.67.  
4; ESI-TOF-MS(positive) m/z calcd for C83H106N26O17
2+［M＋
2H］2+ 870.41; found 870.19.  
5; ESI-TOF-MS(positive) m/z calcd for C80H101N25O16
2+［M＋
2H］2+  834.91; found 834.70. 
6; ESI-TOF-MS(positive) m/z calcd for C75H93N23O14
2+［M＋
2H］2+  770.86; found 770.63. 
 
Supplementary Material 
Experimental details about cytotoxicity, cell culture, HPLC 
chromatogram of compounds and quantification of gene 
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